1,142 results match your criteria Bruton Agammaglobulinemia


Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.

Cancer 2018 Dec 3. Epub 2018 Dec 3.

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Background: In a proportion of patients with chronic lymphocytic leukemia (CLL), resistance to Bruton tyrosine kinase (BTK) inhibitors (BTKi) is attributed to acquired BTK/phospholipase C gamma 2 (PLCG2) mutations. However, knowledge regarding additional genetic lesions associated with BTK/PLCG2 mutations, and gene mutations in patients lacking BTK/PLCG2 mutations, is limited.

Methods: Using targeted deep sequencing, mutations in 29 genes associated with CLL and/or the BCR signaling pathway were assessed in patients with CLL who developed resistance to BTK inhibition with ibrutinib/acalabrutinib at a single institution. Read More

View Article
December 2018

Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.

Br J Haematol 2018 Dec 2. Epub 2018 Dec 2.

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Ibrutinib, a Bruton tyrosine kinase inhibitor, is approved for treatment of various B-cell malignancies. In ibrutinib clinical studies, low-grade haemorrhage was common, whereas major haemorrhage (MH) was infrequent. We analysed the incidence of and risk factors for MH from 15 ibrutinib clinical studies (N = 1768), including 4 randomised controlled trials (RCTs). Read More

View Article
December 2018

Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.

Authors:
Robert Roskoski

Pharmacol Res 2018 Nov 27;139:395-411. Epub 2018 Nov 27.

Blue Ridge Institute for Medical Research, 3754 Brevard Road, Suite 116, Box 19, Horse Shoe, NC 28742-8814, United States. Electronic address:

The EGFR family is among the most investigated receptor protein-tyrosine kinase groups owing to its general role in signal transduction and in oncogenesis. This family consists of four members that belong to the ErbB lineage of proteins (ErbB1-4). The ErbB proteins function as homo and heterodimers. Read More

View Article
November 2018
1 Read

Disseminated Spiroplasma apis Infection in Patient with Agammaglobulinemia, France.

Emerg Infect Dis 2018 Dec;24(12):2382-2386

We report a disseminated infection caused by Spiroplasma apis, a honeybee pathogen, in a patient in France who had X-linked agammaglobulinemia. Identification was challenging because initial bacterial cultures and direct examination by Gram staining were negative. Unexplained sepsis in patients with agammaglobulinemia warrants specific investigation to identify fastidious bacteria such as Spiroplasma spp. Read More

View Article
December 2018

Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.

J Pharm Biomed Anal 2018 Nov 11;164:509-513. Epub 2018 Nov 11.

Drug Metabolism and Interactions Research Lab, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India. Electronic address:

USFDA has approved a novel Bruton tyrosine kinase (BTK) inhibitor acalabrutinib (ACA) for the treatment of mantle cell lymphoma in adults. ACA is more potent and selective with fewer side effects compared to other Bruton tyrosine kinase inhibitors. In the current work a highly sensitive, selective and specific LC-MS/MS method for the estimation of acalabrutinib (ACA) in rat plasma was developed. Read More

View Article
November 2018
2 Reads

Bioavailability, Biotransformation, and Excretion of the Covalent BTK Inhibitor Acalabrutinib in Rats, Dogs, and Humans.

Drug Metab Dispos 2018 Nov 15. Epub 2018 Nov 15.

Acerta Pharma, South San Francisco, CA.

Acalabrutinib is a targeted, covalent inhibitor of Bruton tyrosine kinase (BTK) with a unique 2-butynamide warhead that has relatively lower reactivity than other marketed acrylamide covalent inhibitors. A human [C] microtracer bioavailability study in healthy subjects revealed moderate intravenous clearance (39.4 l/h) and an absolute bioavailability of 25. Read More

View Article
November 2018
4 Reads

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

Blood Adv 2018 Nov;2(21):3012-3024

Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL.

Although the treatment paradigm for chronic lymphocytic leukemia (CLL) is rapidly changing, the disease remains incurable, except with allogeneic bone marrow transplantation, and resistance, relapsed disease, and partial responses persist as significant challenges. Recent studies have uncovered roles for epigenetic modification in the regulation of mechanisms contributing to malignant progression of CLL B cells. However, the extent to which epigenetic modifiers can be targeted for therapeutic benefit in CLL patients remains poorly explored. Read More

View Article
November 2018
3 Reads

Introduction of novel agents in the treatment of Primary CNS Lymphoma.

Neuro Oncol 2018 Nov 13. Epub 2018 Nov 13.

Departments of Neurology and Radiation Oncology, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.

Novel insights into the pathophysiology of Primary Central Nervous System Lymphoma (PCNSL) have identified the B-cell receptor and Toll-like receptor pathway as well as immune evasion and suppressed tumor immune microenvironment as a key mechanism in the pathogenesis of PCNSL. Small molecules and novel agents targeting these aberrant pathways have been introduced into clinical trials targeting the recurrent or refractory PCNSL patient population. Agents like the Bruton Tyrosine Kinase (BTK) inhibitor ibrutinib or immunomodulatory drugs (IMiDs) like pomalidomide and lenalidomide have shown promising high response rates in the salvage setting. Read More

View Article
November 2018
3 Reads

Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.

Biomed Chromatogr 2018 Nov 13:e4435. Epub 2018 Nov 13.

Department of Pharmacy, The Research Hospital, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo, Japan.

Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In this study, we aimed to develop a simple method for determining plasma ibrutinib concentration. The analysis required extraction of a 200 μL plasma sample and precipitation of proteins using solid-phase extraction. Read More

View Article
November 2018
1 Read

Antibodies to protein but not glycolipid structures are important for host defense against .

Infect Immun 2018 Nov 5. Epub 2018 Nov 5.

Laboratory of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC-Sophia Children's Hospital, University Medical Center, Rotterdam, The Netherlands

Antibody responses to () correlate with pulmonary clearance. However, -specific IgG antibodies can cross-react with the myelin glycolipid galactocerebroside (GalC) and cause neurologic disorders. We assessed whether anti-glycolipid antibody formation is part of the physiological immune response to We show that antibodies against -proteins and -glycolipids arise in serum of -infected children and mice. Read More

View Article
November 2018
1 Read

STIM1 R304W causes muscle degeneration and impaired platelet activation in mice.

Cell Calcium 2018 Dec 5;76:87-100. Epub 2018 Oct 5.

Department of Medical Genetics, Oslo University Hospital and University of Oslo, Oslo, Norway. Electronic address:

STIM1 and ORAI1 regulate store-operated Ca entry (SOCE) in most cell types, and mutations in these proteins have deleterious and diverse effects. We established a mouse line expressing the STIM1 R304 W gain-of-function mutation causing Stormorken syndrome to explore effects on organ and cell physiology. While STIM1 R304 W was lethal in the homozygous state, surviving mice presented with reduced growth, skeletal muscle degeneration, and reduced exercise endurance. Read More

View Article
December 2018
4 Reads

A novel Bruton's tyrosine kinase inhibitor acalabrutinib suppresses osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption.

J Periodontol 2018 Nov 2. Epub 2018 Nov 2.

Department of Biochemistry, School of Dentistry, Kyungpook National University, Daegu, Korea.

Background: Periodontitis is not only one of the most prevalent inflammatory diseases among adults, but also commonly linked to numerous systemic conditions including cardiovascular diseases, stroke, and diabetes. Although osteoclasts are responsible for the alveolar bone resorption during periodontitis pathogenesis, the development of pharmacologic strategies targeting these cells has not been vastly fruitful.

Methods: Bone marrow macrophages were cultured in the presence of macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor κB ligand (RANKL) to examine the direct effect of acalabrutinib on osteoclastogenesis. Read More

View Article
November 2018
8 Reads

Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.

Future Oncol 2018 Nov 1. Epub 2018 Nov 1.

UCI Medical Center, Orange, CA 92868, USA.

Acalabrutinib received an accelerated US FDA approval for patients with relapsed/refractory mantle cell lymphoma in 2017 and is currently being evaluated in chronic lymphocytic leukemia (CLL). To date, Ibrutinib is the only Bruton tyrosine kinase (BTK) inhibitor that's approved for treatment of CLL. Acalabrutinib is a second generation BTK inhibitor that binds covalently to the Cys481 residue on BTK and has half maximal inhibitory concentration (IC) of 3 nM. Read More

View Article
November 2018
1 Read

From theory to engineering practice: shared telecommunications knowledge between Oliver Heaviside and his brother and GPO engineer Arthur West Heaviside.

Authors:
Elizabeth Bruton

Philos Trans A Math Phys Eng Sci 2018 Oct 29;376(2134). Epub 2018 Oct 29.

Curator of Technology and Engineering, Science Museum, London, UK

In May 1900, renowned General Post Office (GPO) engineer Arthur West Heaviside gave the Inaugural Address of the Institution of Electrical Engineers Newcastle local section. With a career spanning the pre-Telegraph Act private telegraph networks as well as the subsequent GPO management and licensing of British inland telecommunications, Arthur Heaviside outlined his innovative and experimental work with all three forms of telecommunication in his various GPO engineering roles based in Newcastle. Omitted from the address was the contribution made by Arthur's younger brother, Oliver Heaviside. Read More

View Article
October 2018
1 Read

BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.

Clin Immunol 2018 Dec 16;197:205-218. Epub 2018 Oct 16.

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA; Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address:

Lupus nephritis is a common disease manifestation of SLE, in which immune complex deposition and macrophage activation are important contributors to disease pathogenesis. Bruton's tyrosine kinase (BTK) plays an important role in both B cell and FcgammaR mediated myeloid cell activation. In the current study, we examined the efficacy of BI-BTK-1, a recently described irreversible BTK inhibitor, in the classical NZB × NZW F1 (NZB/W) and MRL/lpr spontaneous mouse models of SLE. Read More

View Article
December 2018
8 Reads

The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase.

Blood Adv 2018 Oct;2(20):2672-2680

Sickle Cell Branch and.

A key inflammatory mechanism recently identified in platelets involves the Nod-like receptor nucleotide-binding domain leucine-rich repeat containing protein 3 (NLRP3) and Bruton tyrosine kinase (BTK), which control activation of caspase-1 within inflammasome complexes. We investigated platelet caspase-1 activity in the context of sickle cell disease (SCD) directly in platelets isolated from SCD patients (n = 24) and indirectly by incubating platelets from healthy subjects with plasma obtained from SCD patients (n = 20), both in steady state and during an acute pain crisis (paired samples). The platelet NLRP3 inflammasome was upregulated in SCD patients under steady state conditions compared with healthy controls, and it was further upregulated when patients experienced an acute pain crisis. Read More

View Article
October 2018
2 Reads

Chronic Aichi Virus Infection in a Patient with X-Linked Agammaglobulinemia.

J Clin Immunol 2018 Oct 11;38(7):748-752. Epub 2018 Oct 11.

Department of Immunology and Microbiology, Laboratory of inborn errors of immunity, KU Leuven, Leuven, Belgium.

View Article
October 2018
12 Reads

Immune Response to Extracellular Vesicles From Human Islets of Langerhans in Patients With Type 1 Diabetes.

Endocrinology 2018 Nov;159(11):3834-3847

Human Islet Transplant Laboratory, Department of Surgery, McGill University Health Centre, Montréal, Québec, Canada.

The autoimmune response that characterizes type 1 diabetes (T1D) has no clear cause. Extracellular vesicles (EVs) play an important role in triggering the immune response in other contexts. Here, we propose a model by which EVs isolated from human islets stimulate proinflammatory immune responses and lead to peripheral blood mononuclear cell (PBMC) activation. Read More

View Article
November 2018
1 Read

Synergies in coordination: a comprehensive overview of neural, computational and behavioral approaches.

J Neurophysiol 2018 Oct 3. Epub 2018 Oct 3.

Exercise and Sport Science, The University of Sydney, Australia.

At face value, the term 'synergy' provides a unifying concept within a fractured field that encompasses complementary neural, computational and behavioral approaches. However, the term is not used synonymously by different researchers, but has substantially different meanings depending on the research approach. With so many operational definitions for the one term, it becomes difficult to use as either a descriptive or explanatory concept, yet it remains pervasive and apparently indispensable. Read More

View Article
October 2018

Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency.

Front Immunol 2018 13;9:1996. Epub 2018 Sep 13.

Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Netherlands.

Chronic lymphocytic leukemia (CLL) can be divided into prognostically distinct subsets with stereotyped or non-stereotyped, mutated or unmutated B cell receptors (BCRs). Individual subsets vary in antigen specificity and origin, but the impact of antigenic pressure on the CLL BCR repertoire remains unknown. Here, we employed μ mice that spontaneously develop CLL, expressing mostly unmutated BCRs of which ~35% harbor V11-2/Vκ14-126 and recognize phosphatidylcholine. Read More

View Article
September 2018
2 Reads

Grounds for Ambiguity: Justifiable Bases for Engaging in Questionable Research Practices.

Sci Eng Ethics 2018 Sep 26. Epub 2018 Sep 26.

School of Humanities, The University of Southern Mississippi, 118 College Drive #5037, Hattiesburg, MS, 39406, USA.

The current study sought to determine research scientists' sensitivity to various justifications for engaging in behaviors typically considered to be questionable research practices (QRPs) by asking them to evaluate the appropriateness and ethical defensibility of each. Utilizing a within-subjects design, 107 National Institutes of Health principal investigators responded to an invitation to complete an online survey in which they read a series of research behaviors determined, in prior research, to either be ambiguous or unambiguous in their ethical defensibility. Additionally, each behavior was paired with either an ostensibly sound or unsound reason for the behavior. Read More

View Article
September 2018
7 Reads

Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 Dec 18;18(12):803-813.e7. Epub 2018 Aug 18.

The Leeds Teaching Hospitals, St. James University Hospital, Leeds, United Kingdom.

Background: Ibrutinib compared with ofatumumab significantly improves progression-free and overall survival in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Patients And Methods: Measures of well-being were assessed in RESONATE, where previously treated patients with CLL/SLL were randomized to receive ibrutinib 420 mg/day (n = 195) or ofatumumab (n = 196) for up to 24 weeks. Endpoints included hematologic function, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), disease-related symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaires Core 30 (EORTC QLQ-C30), and medical resource utilization. Read More

View Article
December 2018
11 Reads

Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules.

Am Soc Clin Oncol Educ Book 2018 May(38):604-615

From the Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Neurology, Weill Cornell Medical College, New York, NY.

Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the brain, eyes, and cerebrospinal fluid (CSF) without evidence of systemic spread. PCNSL is an uncommon tumor, and only four randomized trials and one phase III trial have been completed so far, all in the first-line setting. The prognosis of patients with PCNSL has improved during the past few decades with the introduction of high-dose methotrexate (HD-MTX), which now serves as the backbone of all first-line treatment regimens. Read More

View Article
May 2018
1 Read

The IgE memory reservoir in food allergy.

J Allergy Clin Immunol 2018 Nov 7;142(5):1441-1443. Epub 2018 Sep 7.

McMaster Immunology Research Centre (MIRC), Department of Pathology & Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address:

View Article
November 2018
7 Reads

First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.

Hematol Oncol Clin North Am 2018 Oct 19;32(5):853-864. Epub 2018 Jul 19.

Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Electronic address:

Waldenström macroglobulinemia (WM) is an indolent B-cell lymphoma that is heavily dependent on Bruton tyrosine kinase (BTK) hyperactivation. Ibrutinib is a first-generation BTK inhibitor that has shown high activity and durable responses in patients with relapsed/refractory WM. Newer and more selective BTK inhibitors are currently being tested in several clinical trials and are expected to address the toxicity and the acquired resistance observed in patients receiving ibrutinib. Read More

View Article
October 2018
5 Reads

Association of blood IgG with tumor necrosis factor-alpha and clinical course of chronic lymphocytic leukemia.

EBioMedicine 2018 Sep 30;35:222-232. Epub 2018 Aug 30.

Biology Platform, Sunnybrook Research Institute, Toronto M4N 3M5, Canada.

The intrinsic humoral immunodeficiency of chronic lymphocytic leukemia (CLL) is often managed with immunoglobulin replacement therapy (IgRT) to maintain IgG levels in the low-normal range (6-8 g/L) but optimal targets for IgG and timing to commence IgRT are unclear. IgG levels fell near 6 g/L at rates of -0.85±0. Read More

View Article
September 2018
1 Read

From activism to secrecy: Contemporary experiences of living with HIV in London in people diagnosed from 1986 to 2014.

Health Expect 2018 Dec 30;21(6):1134-1141. Epub 2018 Aug 30.

School of Public Health, Imperial College London, London, UK.

Background: Successes in biomedicine have transformed HIV from a debilitating and frequently fatal infection to a chronic, manageable condition.

Objective: To explore how the contemporary metanarrative of HIV as a chronic condition is understood by patients and how it varies depending on when they were diagnosed.

Design: Qualitative interviews with 52 people living with HIV who were diagnosed during different phases in the history of the epidemic. Read More

View Article
December 2018
1 Read

Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.

Br J Haematol 2018 Oct 20;183(2):212-224. Epub 2018 Aug 20.

Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.

In chronic lymphocytic leukaemia (CLL) patients, treatment with the Bruton tyrosine kinase inhibitor ibrutinib induces a rapid shift of tumour cells from lymph nodes (LN) to peripheral blood (PB). Here, we characterized in depth the dynamics of ibrutinib-induced inflammatory, transcriptional and cellular changes in different compartments immediately after treatment initiation in seven relapsed/refractory CLL patients. Serial PB and LN samples were taken before start and during the first 29 days of treatment. Read More

View Article
October 2018
1 Read

Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment.

Rheumatology (Oxford) 2018 Dec;57(12):2149-2157

Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Solna, Sweden.

Objectives: To investigate the expression of IL-18 in symptomatic and asymptomatic muscle tissues of patients with PM and DM and the effects of conventional immunosuppressive treatment on such expression.

Methods: Two cohorts of patients were included in this study. The first cohort consisted of 10 new-onset myositis patients. Read More

View Article
December 2018
3 Reads

Identification of attractive blend for spotted wing drosophila, , from apple juice.

J Pest Sci (2004) 2018 22;91(4):1251-1267. Epub 2018 Jun 22.

Invasive Insect Biocontrol and Behavior Laboratory, Agricultural Research Service, United States Department of Agriculture, Bldg. 007, Rm. 312, BARC-W, Beltsville, MD 20705 USA.

, commonly known as the spotted wing drosophila (SWD), is an exotic fruit fly from Southeast Asia that was introduced to the temperate regions of North America and Europe in 2008. It attacks a wide variety of fruits and has become a devastating pest of soft-skinned fruit crops. Due to the rapid spread of SWD across the newly invaded continents, fresh fruit markets have a zero-tolerance policy regarding infestation. Read More

View Article
June 2018
8 Reads

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Cancer Discov 2018 Oct 9;8(10):1300-1315. Epub 2018 Aug 9.

Department of Internal Medicine, Division of Hematology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

Targeted inhibition of Bruton tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has improved outcomes for patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL). Here, we describe preclinical investigations of ARQ 531, a potent, reversible inhibitor of BTK with additional activity against Src family kinases and kinases related to ERK signaling. We hypothesized that targeting additional kinases would improve global inhibition of signaling pathways, producing more robust responses. Read More

View Article
October 2018
16 Reads

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Br J Haematol 2018 Oct 6;183(2):196-211. Epub 2018 Aug 6.

Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, USA.

CD38 is expressed on Waldenström macroglobulinaemia (WM) cells, but its role as a therapeutic target remains undefined. With recent approval of the anti-CD38 monoclonal antibody, daratumumab (Dara), we hypothesized that blocking CD38 would be lethal to WM cells. In vitro Dara treatment of WM cells (including ibrutinib-resistant lines) elicited antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cell phagocytosis (ADCP) and direct apoptosis. Read More

View Article
October 2018
6 Reads

Risk of Major Bleeding with Ibrutinib.

Clin Lymphoma Myeloma Leuk 2018 Nov 1;18(11):755-761. Epub 2018 Aug 1.

Division of Hematology-Oncology, Department of Medicine and Cancer Center, University of Virginia Health System, Charlottesville, VA.

Background: The Bruton tyrosine kinase inhibitor, ibrutinib, is an effective therapy against mature B-cell malignancies. Although generally well tolerated, serious bleeding emerged during developmental clinical trials as an unexpected, although uncommon, adverse event. As the use of ibrutinib increases outside of the clinical trial setting and in patients with more comorbidities, the rate of major bleeding could be greater. Read More

View Article
November 2018
11 Reads

Clinical and genetic profiles of patients with X-linked agammaglobulinemia from southeast Turkey: Novel mutations in BTK gene.

Allergol Immunopathol (Madr) 2018 Jul 30. Epub 2018 Jul 30.

Department of Medical Genetics, Çukurova University Faculty of Medicine, Adana, Turkey.

Background: X-linked agammaglobulinemia (XLA) is characterized by absent or severely reduced B cells, low or undetectable immunoglobulin levels, and clinically by extracellular bacterial infections which mainly compromise the respiratory tract. We aimed to analyze the clinical, immunological and genetic characteristics of 22 male children with XLA.

Methods: Twenty-two children with XLA from 12 unrelated families were enrolled in this study. Read More

View Article
July 2018
4 Reads

Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 Oct 28;18(10):648-657.e15. Epub 2018 Jun 28.

Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA.

Background: Multiple studies have demonstrated the efficacy and safety of ibrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL.

Patients And Methods: We conducted an integrated safety analysis to characterize the frequency, severity, natural history, and outcomes of adverse events (AEs) with ibrutinib versus comparators. Read More

View Article
October 2018
2 Reads

New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?

Expert Rev Hematol 2018 Sep 2;11(9):749-756. Epub 2018 Aug 2.

b Department of Hematology and Hematopoietic Cell Transplantation , City of Hope National Medical Center , Duarte , CA , USA.

Introduction: Despite recent prognostic improvements, mantle cell lymphoma (MCL) remains incurable. Bruton tyrosine kinase (BTK) is a key receptor in B-cell tumorigenesis, and the benefits of the first BTK inhibitor, ibrutinib, are becoming clear in MCL. However, off-target activities, which contribute to ibrutinib-related adverse events, suggest potential for further improvement of this drug class. Read More

View Article
September 2018
1 Read

European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.

Leukemia 2018 Sep 23;32(9):1883-1898. Epub 2018 Jul 23.

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.

The introduction of novel agents in the management of multiple myeloma and related plasma cell dyscrasias has changed our treatment approaches and subsequently the outcome of patients. Due to current advances, the European Myeloma Network updated the diagnostic and therapeutic recommendations for patients with Waldenström's macroglobulinemia (WM), AL-amyloidosis, monoclonal immunoglobulin deposition disease (MIDD), POEMS syndrome, and primary plasma cell leukemia. For patients with WM, the combination of rituximab with chemotherapy remains the treatment cornerstone, while the Bruton-tyrosine kinase inhibitor ibrutinib has been introduced and approved for relapsed/refractory disease. Read More

View Article
September 2018
9 Reads

The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).

Eur J Haematol 2018 Jul 20. Epub 2018 Jul 20.

Pharmacyclics, LLC, an AbbVie Company, Sunnyvale, CA, USA.

Objectives: Bruton's tyrosine kinase (BTK) and tyrosine kinase expressed in hepatocellular carcinoma (TEC) are expressed by human platelets. These kinases participate in platelet activation through the collagen receptor glycoprotein VI and may perform overlapping functions. In clinical studies, BTK inhibitors (ibrutinib, acalabrutinib, tirabrutinib, zanubrutinib) have been associated with increased bleeding risk, which may result from inhibition of BTK alone or of both BTK and TEC, although the role of TEC in bleeding risk remains unclear. Read More

View Article
July 2018
1 Read

empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.

BMJ Case Rep 2018 Jul 18;2018. Epub 2018 Jul 18.

Infectious Diseases and Microbiology, Concord Repatriation General Hospital, Concord, New South Wales, Australia.

We report a case of pulmonary infection complicated by empyema in a 79-year-old man with diffuse large B-cell lymphoma treated with R-CHOP and ibrutinib. A literature review identified 25 cases of cryptococcal pleural disease published since 1980. Most cases were caused by the species in immunocompromised hosts with an exudative pleural effusion and lymphocyte-predominant infiltrate. Read More

View Article
July 2018
4 Reads

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Blood 2018 Sep 17;132(10):1039-1049. Epub 2018 Jul 17.

Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center.

The clinical success of ibrutinib validates Bruton tyrosine kinase (BTK) inhibition as an effective strategy for treating hematologic malignancies, including chronic lymphocytic leukemia (CLL). Despite ibrutinib's ability to produce durable remissions in patients, acquired resistance can develop, mostly commonly by mutation of C481 of BTK in the ibrutinib binding site. Here, we characterize a novel BTK inhibitor, GDC-0853, to evaluate its preclinical efficacy in ibrutinib-naive and ibrutinib-resistant CLL. Read More

View Article
September 2018
3 Reads

New biologics in the treatment of urticaria.

Curr Opin Allergy Clin Immunol 2018 Oct;18(5):425-431

Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.

Purpose Of Review: Symptomatic management of chronic spontaneous urticaria (CSU) basically depends on second-generation H1 antihistamines and omalizumab. Omalizumab is a game changer in the management, but still there is a need for new targets and new biologics targeting new pathways in the treatment which will provide long-lasting remission, which will be given orally and which will be cheaper. This review will focus on new biologics that are underway of production or are already under use for different disorders but could be beneficial for the treatment of Chronic urticaria. Read More

View Article
October 2018
5 Reads

Ibrutinib in the management of Waldenstrom macroglobulinemia.

J Oncol Pharm Pract 2018 Jan 1:1078155218786037. Epub 2018 Jan 1.

1 Grand Strand Regional Medical Center, Myrtle Beach, USA.

Bruton tyrosine kinase plays a critical role in hastening cell proliferation. Bruton tyrosine kinase inhibitors are a class of immunotheraputic agents that disrupt this signaling pathway. Ibrutinib, a novel Bruton tyrosine kinase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of Waldenstrom macroglobulinemia in patients who have failed treatment with other agents, has emerged as an important therapeutic agent in the management of Waldenstrom macroglobulinemia and other plasma cell dyscrasias. Read More

View Article
January 2018
7 Reads

Novel agents for primary central nervous system lymphoma: evidence and perspectives.

Blood 2018 Aug 9;132(7):681-688. Epub 2018 Jul 9.

Department of Hematology/Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany.

Primary central nervous system lymphoma (PCNSL) is a rare aggressive extranodal non- Hodgkin lymphoma. Although high remission rates can be achieved with high-dose methotrexate-based immunochemotherapy, risk of relapse and associated death is still substantial in at least a third of patients. Novel agents for treating lymphoid malignancies have substantially enriched treatment options for PCNSL. Read More

View Article
August 2018
13 Reads

Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.

Oncotarget 2018 Jun 19;9(47):28547-28560. Epub 2018 Jun 19.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Saga University, Saga, Japan.

Despite the development of the novel Bruton tyrosine kinase inhibitor ibrutinib, mantle cell lymphoma (MCL) remains an incurable B-cell non-Hodgkin lymphoma. BMI-1 is required for the self-renewal and maintenance of MCL-initiating stem cells. Upregulation of BMI-1 has been reported in MCL patients, especially in those with refractory/relapsed disease. Read More

View Article
June 2018
9 Reads

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

Br J Haematol 2018 Sep 5;182(5):654-669. Epub 2018 Jul 5.

Northern Blood Research Centre, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Sydney, Australia.

Despite significant advances in treatment, chronic lymphocytic leukaemia (CLL) remains an incurable disease. Ibrutinib and idelalisib, which inhibit Bruton Tyrosine kinase (BTK) and phosphoinositol-3 (PI3) kinase-δ respectively, have become important treatment options for the disease and demonstrate the potential of targeting components of the B-cell receptor-signalling pathway. IBL-202 is a dual inhibitor of the PIM and PI3 kinases. Read More

View Article
September 2018
6 Reads

Structural and functional analysis of Dickkopf 4 (Dkk4): New insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins.

J Biol Chem 2018 Aug 20;293(31):12149-12166. Epub 2018 Jun 20.

From the Leicester Institute of Structural and Chemical Biology and

Dickkopf (Dkk) family proteins are important regulators of Wnt signaling pathways, which play key roles in many essential biological processes. Here, we report the first detailed structural and dynamics study of a full-length mature Dkk protein (Dkk4, residues 19-224), including determination of the first atomic-resolution structure for the N-terminal cysteine-rich domain (CRD1) conserved among Dkk proteins. We discovered that CRD1 has significant structural homology to the Dkk C-terminal cysteine-rich domain (CRD2), pointing to multiple gene duplication events during Dkk family evolution. Read More

View Article
August 2018
20 Reads

Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.

Int J Mol Sci 2018 Jun 13;19(6). Epub 2018 Jun 13.

Department of Hematology, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is one of the well-recognized extranodal lymphomas commonly addicted to the B-cell receptor-MYD88 superpathway. We aimed to describe the genomic changes in a patient who progressed through treatment with ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor. An 80-year-old woman presented with multiply relapsed PCDLBCL-LT after multiple lines of chemoimmunotherapy and radiotherapy. Read More

View Article
June 2018
16 Reads

A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.

Future Oncol 2018 Sep 5;14(22):2229-2237. Epub 2018 Jun 5.

CCC Ulm, University Hospital Ulm, Ulm, Germany.

Waldenström macroglobulinemia (WM), an incurable B-cell malignancy, is sensitive to Bruton tyrosine kinase (BTK) inhibition with ibrutinib, a first-generation BTK inhibitor. Off-target effects of ibrutinib against TEC- and EGFR-family kinases are implicated in some adverse events. Patients with CXCR4 and MYD88 mutations or who are MYD88 have less sensitivity to ibrutinib than those with MYD88 and CXCR4 disease. Read More

View Article
September 2018
2 Reads

Correction to: Clinical outcomes of patients undergoing primary percutaneous coronary intervention for acute myocardial infarction requiring the intensive care unit.

J Intensive Care 2018 31;6:32. Epub 2018 May 31.

1Department of Anesthesia and Intensive Care, Papworth Hospital, Cambridge, England.

[This corrects the article DOI: 10.1186/s40560-018-0275-y.]. Read More

View Article